Replies to post #150273 on Biotech Values

[DewDiligence]

Webcast slides from BAX Investor Day

CEO overview (27 pages):
http://phx.corporate-ir.net/External.File?t=1&item=VHlwZT0yfFBhcmVudElEPTQ4MzY4ODV8Q2hpbGRJRD00ODE2NjM

Financial overview (21 pages):
http://phx.corporate-ir.net/External.File?t=1&item=VHlwZT0yfFBhcmVudElEPTQ4MzY4ODV8Q2hpbGRJRD00ODE2NjI

R&D (22 pages):
http://phx.corporate-ir.net/External.File?t=1&item=VHlwZT0yfFBhcmVudElEPTQ4MzY4ODV8Q2hpbGRJRD00ODE2Njc

Medical Products segment (40 pages):
http://phx.corporate-ir.net/External.File?t=1&item=VHlwZT0yfFBhcmVudElEPTQ4MzY4ODV8Q2hpbGRJRD00ODE2Njk

Bioscience segment (68 pages):
http://phx.corporate-ir.net/External.File?t=1&item=VHlwZT0yfFBhcmVudElEPTQ4MzY4ODV8Q2hpbGRJRD00ODE2NzI

International business (21 pages):
http://phx.corporate-ir.net/External.File?t=1&item=VHlwZT0yfFBhcmVudElEPTQ4MzY4ODV8Q2hpbGRJRD00ODE2NzM

[DewDiligence]

Webcast slides from BAX Investor Day:

http://investor.baxter.com/phoenix.zhtml?c=86121&p=irol-calendar

The slides are in six parts:

• CEO overview (27 pages)
• Financial overview (21 pages)
• R&D (22 pages)
• Medical Products segment (40 pages)
• Bioscience segment* (68 pages)
• International business (21 pages)

*Probably the most interesting set for readers of this board.

[DewDiligence]

Slide from BAX Investor Day on MNTA collaboration;
no new hints regarding the identities of the first three
FoB compounds in the collaboration: